Trials / Recruiting
RecruitingNCT06985147
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Disc Medicine, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DISC-3405 | DISC-3405 is administered subcutaneously. |
Timeline
- Start date
- 2025-08-12
- Primary completion
- 2027-02-01
- Completion
- 2029-02-01
- First posted
- 2025-05-22
- Last updated
- 2026-03-04
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06985147. Inclusion in this directory is not an endorsement.